References UK clinical guidance from the NHS, the British HIV Association (BHIVA), and the British Association for Sexual Health and HIV (BASHH). Last updated: April 2026.
PrEP failure — acquiring HIV while taking PrEP — is extremely rare. When taken as prescribed, PrEP reduces the risk of HIV by over 99%. The vast majority of reported breakthrough infections are linked to inconsistent use, meaning missed doses rather than true drug failure. However, a tiny number of cases have occurred despite confirmed adherence.
Here’s what we know about why PrEP can fail, and what it means for you.
Order a discreet home HIV test
How Rare Is PrEP Failure?
Across major clinical trials involving tens of thousands of participants, confirmed breakthrough infections with documented good adherence number in the single digits. The overwhelming evidence is that PrEP works when taken correctly.
Reasons for Breakthrough Infection
| Cause | How Common |
|---|---|
| Missed doses or inconsistent use | By far the most common reason |
| Starting PrEP during undiagnosed acute HIV infection | Rare but documented |
| Drug-resistant HIV strain | Very rare |
| Malabsorption or drug interaction | Theoretical |
| True pharmacological failure despite perfect adherence | Extremely rare |
How to Minimise Your Risk
- Take PrEP consistently — daily dosing is the most reliable approach
- Attend clinic appointments — HIV testing every 3 months catches early infection
- Report symptoms of acute HIV — fever, rash, sore throat, swollen glands within 2-4 weeks of a risky exposure. If you have these symptoms, seek urgent testing
- Test before starting PrEP — always confirm you are HIV-negative before beginning
- Don’t share PrEP — unsupervised use without testing risks starting while already HIV-positive
What If I Think PrEP Has Failed?
If you test positive for HIV while on PrEP:
- Your clinic will confirm the result with laboratory tests
- They will check for drug resistance
- You will be started on a full HIV treatment regimen
- PrEP alone is not enough to treat HIV — a full regimen is needed
The most important thing is not to panic. HIV is a treatable condition, and outcomes are excellent with prompt treatment.
Event-Based Dosing (2-1-1)
Event-based PrEP (taking pills around the time of sex rather than daily) is effective for men who have sex with men but requires careful planning. Missing doses in the 2-1-1 schedule can reduce protection. If your sexual activity is frequent or unpredictable, daily dosing is more reliable.
Read more: PrEP benefits and risks | PrEP and drug resistance | What is HIV?
Frequently Asked Questions
Should I worry about PrEP failure?
Not if you’re taking PrEP as prescribed and attending regular clinic visits. Breakthrough infections are exceptionally rare with consistent use.
Can drug-resistant HIV defeat PrEP?
In theory, HIV resistant to tenofovir and emtricitabine could reduce PrEP effectiveness. In practice, this is extremely rare and most circulating HIV strains are fully susceptible to PrEP drugs.
Is daily PrEP safer than on-demand?
Daily dosing provides the highest and most consistent drug levels. On-demand (2-1-1) is effective when used correctly but leaves less room for error.
Related reading
- Are HIV Tests Accurate If You're on PrEP, PEP or ART?
- Choosing the Right PrEP Drug: Truvada vs Descovy
- Post-Exposure Prophylaxis (PEP) for HIV
- Pre-Exposure Prophylaxis (PrEP) for HIV
- PrEP and Sexually Transmitted Infections
Sources
- NHS — Sexual health conditions
- BASHH — UK clinical guidelines for STI management
- British HIV Association (BHIVA) — HIV treatment guidelines
- Terrence Higgins Trust — sexual health information
- UK Health Security Agency — STI surveillance data
Steve Page is a recognised expert on Sexually Transmitted Diseases (STDs) and STD treatments, having published numerous articles in peer-reviewed journals and presented his research at conferences around the world. He has an in-depth understanding of the latest medical research on STDs, and is an advocate for the development of new treatments and protocols to improve the health of those affected. In addition to his research, he has dedicated his career to understanding the causes and symptoms of STDs, as well as how to best treat those impacted.
